Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Lilly and Merck.

For further information concerning Lilly grant funding, visit

Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer

Release Date: July 31, 2017
Expiration Date: July 31, 2018
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in Chicago in June 2017, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 4 abstracts selected by the program faculty, Ricardo Alvarez, MD, and Sara Hurvitz, MD, as the most clinically relevant from the meeting. For each abstract, a short summary of key clinical data is accompanied by faculty commentary that provides insight into how new data fit into the current field, and how clinicians can apply these findings to their clinical practice to improve patient care. Interactive questions are interspersed throughout the activity to enable engagement, learning, and self-assessment.

CME Activity Table of Contents

  • Abemaciclib Plus Fulvestrant for Patients With Hormone Receptor-Positive, HER2-Negative, Advanced Breast Cancer After Progression on Endocrine Therapy: Results of the Phase III MONARCH 2 Trial
  • Adjuvant Pertuzumab Plus Trastuzumab With Chemotherapy for Early, HER2-Positive Breast Cancer: Results of the APHINITY Trial
  • PARP Inhibition for HER2-Negative, BRCA-Mutated, Metastatic Breast Cancer: Results of the Phase III OlympiAD Trial of Olaparib
  • PD-1 Inhibition With Pembrolizumab for Previously Treated, Metastatic, Triple-Negative Breast Cancer: Results of the Phase II KEYNOTE-086 Trial

Acknowledgment of Commercial Support

This activity is supported by educational grants from Lilly and Merck.

For further information concerning Lilly grant funding, visit

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "educational content/audio files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with breast cancer. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Detail the design and endpoints of recent noteworthy clinical trials that evaluated novel strategies for the management of breast cancer
  2. Explain emerging evidence on novel strategies for the treatment of breast cancer
  3. Place into clinical context emerging evidence concerning novel approaches in the care of patients with breast cancer

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Faculty, Staff, and Planners' Disclosures


Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, BI Pharma, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, PUMA, Merrimack, Medivation, Dignitana, OBI Pharma, BioMarin, Cascadian, Seattle Genetics; Other (Paid Travel): Lilly, Novartis, OBI Pharma, Bayer

Ricardo H. Alvarez, MD, MSc
Director, Cancer Research at CTCA- Atlanta
Leader, Breast Cancer Institute CTCA
Clinical Assistant Professor, Augusta University
Augusta GA
Cancer Treatment Centers of America®
Atlanta, GA

Disclosure: Speakers Bureau: Eisai, Inc.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By